Royalty Pharma Sub-Manager
Latest statistics and disclosures from Royalty Pharma Sub-Manager's latest quarterly 13F-HR filing:
- Top 5 stock holdings are CYTK, ZBIO, Kailera Therapeutics, BHVN, and represent 100.00% of Royalty Pharma Sub-Manager's stock portfolio.
- Added to shares of these 1 stock: Kailera Therapeutics (+$54M).
- Started 1 new stock position in Kailera Therapeutics.
- Reduced shares in these 1 stock: .
- Sold out of its position in BCRX.
- Royalty Pharma Sub-Manager was a net buyer of stock by $18M.
- Royalty Pharma Sub-Manager has $242M in assets under management (AUM), dropping by 40.03%.
- Central Index Key (CIK): 0002081668
Tip: Access up to 7 years of quarterly data
Positions held by Royalty Pharma Sub-Manager consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Royalty Pharma Sub-Manager
Royalty Pharma Sub-Manager holds 4 positions in its portfolio as reported in the June 2026 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Cytokinetics (CYTK) | 34.5 | $84M | 980k | 85.19 |
|
|
| Zenas Biopharma (ZBIO) | 25.1 | $61M | 2.4M | 25.38 |
|
|
| Kailera Therapeutics | 22.4 | $54M | NEW | 2.5M | 22.03 |
|
| Biohaven (BHVN) | 18.1 | $44M | 2.9M | 14.88 |
|
Past Filings by Royalty Pharma Sub-Manager
SEC 13F filings are viewable for Royalty Pharma Sub-Manager going back to 2026
- Royalty Pharma Sub-Manager 2025 Q4 restated filed Aug. 21, 2026
- Royalty Pharma Sub-Manager 2026 Q1 restated filed Aug. 21, 2026
- Royalty Pharma Sub-Manager 2026 Q2 restated filed Aug. 21, 2026